We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Since the pandemic began, the Gates Foundation has previously spent $1.9 billion to support research and development and manufacturing efforts for COVID-19 vaccines, drugs and tests. Read More
Takeda Pharmaceutical has signed a risk-sharing agreement with Point32Health, the second-largest health plan in New England, that has Takeda returning a portion of the cost of its lung cancer drug Alunbrig in circumstances when it doesn’t work. Read More
Chinese biopharmaceutical company BeiGene is refusing to dissolve its Abraxane cancer drug deal with Bristol Myers Squibb (BMS), saying that the U.S. company’s proposed pull-out deal is just an attempt to stem potential arbitration costs, according to a new filing with the Securities and Exchange Commission (SEC). Read More
Sanofi said that supply for all four formulations of Kevzara ― 150 mg, 200 mg, prefilled syringe and auto-injector ― are expected to be limited until early 2022 based on current projections. Read More
Pacira BioSciences will pay close to $427.5 million to buy pain management company Flexion Therapeutics, maker of Zilretta, a nonopioid injection approved in 2017 for chronic osteoarthritis. Read More
In the second announcement this week of a large drugmaker acquiring a rare diseases-focused company, Merck has agreed to buy Accleron Pharma for $11.5 billion to strengthen its cardiovascular pipeline. Read More